Trial Profile

Phase II study evaluating the combination of capecitabine and oxaliplatin in patients with gastric cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 Nov 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Oxaliplatin
Indications Gastric cancer
Focus Therapeutic Use

Most Recent Events

20 Nov 2015 Results published in Chugai Pharmaceuticals media release.
20 Nov 2015 According to Chugai Pharmaceuticals media release, company announced that it has obtained supplemental approval from the Japanese Ministry of Health, Labour and Welfare (MHLW).
31 Jul 2015 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com